Further NEO 212 Studies Shows Ability To Slow GBM Cell Invasion at Sub-Cytotoxic Dose
NEO 212 Sub-Cytotoxic Doses Capable of Inhibiting Glioma Stem Cell Invasion.
Authors: Thomas C. Chen1, Nagore I. Marín-Ramos1, and Florance M. Hofman2
Glioblastoma multiforme (GBM) is a malignant brain tumor characterized by its extensive vascularity, aggressiveness, and invasiveness, where cell migration plays an important role in tumor progression. Its poor prognosis is associated with high recurrence, and resistance to the current standard of care chemotherapy, temozolomide (TMZ). Despite great progress made in surgery and therapies, there has been little improvement in patient outcomes over the past decade. Once the tumor recurs, there are few treatment options available to patients. Thus, chemotherapeutic agents with greater efficacy than TMZ are badly needed.
NeOnc Technologies has performed several studies showing the efficacy of its TMZ and Peryllil Alcohol(POH) conjugate to provide an enhanced ability to slow and stop GBM cell growth above the use of TMZ alone. In addition, a preliminary study by NeOnc Technologies has shown that its’ NEO 212 conjugate has an impact on slowing the invasion of Glioma Stem Cells (GSM) which is one of the mechanisms attributed to the difficulty in treating GBM cancer.
In the previous studies, NeOnc Technologies was able to determine the maximum tolerated dose for its NEO 212 conjugate that had the greatest impact on the tumor cells while not affecting the test animals’ overall ability to tolerate treatment.
An additional study has now shown that NEO 212 is effective at slowing GBM migration at substantially lower concentrations thereby providing minimal toxicity to the test subject. This ability to block GSC migration and invasion in vivo at lower concentrations, as well as its selective cytotoxicity for tumor cells, are unusual in chemotherapy, making NEO212 an ideal candidate for the treatment of newly diagnosed and TMZ-resistant recurrent gliomas.
Departments of 1Neurosurgery, and 2Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA.